Phase 2 N=22 Pilot Randomized Trial With Flecainide in ARVC Patients
Arrhythmogenic Right Ventricular Cardiomyopathy
Primary: Number of Ventricular Ectopic Beats (VEBs) Per Day — 2685; 677 number of VEBs per day — p=<0.0001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=22 Targeting the Right Ventricle in Pulmonary Hypertension
Pulmonary Hypertension
Primary: Changes in Right Ventricular Ejection Fraction — 5.8; -4.7; 0.49 percentage
N/A N=18 Multimodality Assessment of Ventricular Scar Arrhythmogenicity.
Ventricular Tachycardia
Primary: Electrogram Duration at Digital Twin Predicted Sites Compared to Non-predicted Sites — 77.5; 65.7 ms
Phase 3 N=68 A Clinical Trial Utilizing Dantrolene in Patients With Ventricular Arrhythmias.
Ventricular Tachycardia
Primary: Number of Participants With Inducible Sustained Ventricular Tachycardia/ Ventricular Fibrillation (VT/VF) Utilizing Standardized Stimulation Protocol. — 4; 9 Participants
Phase 4 N=22 Targeting Right Ventricle in Pulmonary Hypertension Gilead
Pulmonary Hypertension
Primary: Absolute Change From Baseline Right Ventricular Ejection Fraction (the Unit is Percentage) — 7.56; -3.99 percentage
N/A N=120 Training-induced Increased Left Ventricular Trabeculation
Athletes Heart · Left Ventricular Hypertrabeculation
Primary: Thickness of Compacted Myocardial Tissue (cm) — 0.53; 0.56; 0.8; 0.85 cm — p=0.44
N/A N=42 Eplerenone for Subclinical Cardiomyopathy in Duchenne Muscular Dystrophy
Duchenne Muscular Dystrophy
Primary: 12-month Change in Myocardial Strain — 2.2; 1.0 percent change in heart dimension
N/A N=22 Endothelial Function and Cardiac Output in RV Pacing
Bradycardia
Primary: Endothelial Function Assessed by Flow Mediated Vasodilatation — 1.96; 1.73 EndoPAT index (EnFI)
N/A N=17 REnal Sympathetic dEnervaTion as an a Adjunct to Catheter-based VT Ablation
Ventricular Tachycardia
Primary: Freedom From First Event Requiring ICD Therapy — 62.5; 50; 62.5; 37.5 probability of freedom
Phase 4 N=1,962 RIGHT: Rhythm ID Going Head-to-Head Trial
Tachycardia
Primary: Number of Patients With Inappropriate Ventricular Tachycardia (VT)/Ventricular Fibrillation (VF) Therapy (Shock or Antitachycardia Pacing [ATP]) After the Pre-Discharge…
Phase 3 N=33 SOAR: Study Observing Antiarrhythmic Remodelling Using LGE-MRI
Atrial Fibrillation
Primary: LA Fibrosis — 24.6; 16.8 percentage of fibrosis
N/A N=3,889 Improve Sudden Cardiac Arrest Study
Sudden Cardiac Arrest · Ventricular Arrythmia
Primary: Time to the First Occurrence of a Ventricular Arrhythmia — 32.5; 18.3 Estimated 24-Month VT-VF Pct of Patients
N/A N=1 Stereotactic Ablative Radiotherapy for Refractory Ventricular Tachycardia
Refractory Ventricular Tachycardia
Primary: ICD (Implantable Cardioverter Defibrillator) Shock Free Survival — 1 Participants
N/A N=15 Right Ventricular Function and Exercise Capacity in Patients With Continuous-flow Left Ventricular Assist Devices
Heart Failure
Primary: Peak Oxygen Uptake — 15 ml/kg/min
Phase 2 N=25 Contrast Enhanced 3D Echocardiographic Quantification of Right Ventricular Volumes in Repaired CHD
Tetralogy of Fallot · Pulmonary Insufficiency
Primary: Accuracy of 3D Echocardiography Based Measurements of Right Ventricular Size Compared to MRI Derived Values. — 187.1; 175.4; 205.0; 86.0 ml
N/A N=1,223 DISCOVERY: Diagnostic Data and Genetic Polymorphisms in ICD Patients.
Death, Sudden, Cardiac · Ventricular Fibrillation · Tachycardia
Primary: Number of Patients With Ventricular Arrhythmia <400 Msec. by GNAS c.393C>T Genotype — 63; 136; 98 participants with VT < 400 msec
N/A N=98 ENHANCE-Efficacy of the Presence of Right Ventricular Apical Pacing Induced Ventricular Dyssynchrony as a Guiding Parameter for Biventricular Pacing in Patients With Bradycardia and Normal Ejection Fraction
Bradycardia
Primary: LVEF — 64.22; 63.14; 59.96 % LVEF — p=0.1734
Phase 4 N=526 ADVANCE CRT - D: Antitachycardia Pacing (ATP) Delivery for Painless Implantable Cardioverter Defibrillator (ICD) Therapy
Tachycardia, Ventricular · Ventricular Fibrillation
Primary: Efficacy of Anti Tachycardia Pacing (ATP) Therapy (Burst, 8 Pulses, 88 %, 1 Sequence) to Terminate All Types of Ventricular Tachycardia. — 64.7; 68.2 Percent of VT…
N/A N=50 The Right Ventricular Pulmonary Circulation Continuum in Mitral Valve Disease Study
Mitral Regurgitation · Pulmonary Hypertension
Primary: Impaired Post-operative Functional Capacity — 35 Participants
Phase 4 N=87 REPAIR: Right vEntricular Remodeling in Pulmonary ArterIal hypeRtension
Pulmonary Arterial Hypertension
Primary: Change From Baseline in Right Ventricular Stroke Volume (RVSV) to Week 26 — 15.17 milliliters (mL)
N/A N=610 REsynchronization reVErses Remodeling in Systolic Left vEntricular Dysfunction (REVERSE)
Heart Failure
Primary: Percentage of Patients Worsened for Clinical Composite Response — 21.5; 16 Percentage of participants worsened — p=0.10
N/A N=33 Novel Cardiac Magnetic Resonance Imaging to Define a Unique Restrictive Cardiomyopathy in Sickle Cell Disease
Sickle Cell Disease
Primary: Frequency of the Diffuse Myocardial Fibrosis Phenotype — 5; 10; 10; 1 Participants
N/A N=312 CARISMA : Cardiac Arrhythmias and Risk Stratification After MyoCardial Infarction
Acute Myocardial Infarction
Primary: ECG-documented Ventricular Fibrillation or Symptomatic Sustained Ventricular Tachycardia (VT) — 25; 8; 3; 2 participants
N/A N=523 Risk Stratification in Patients With Preserved Ejection Fraction
Myocardial Infarction
Primary: Number of Participants With Major Arrhythmic Events (MAEs) - Present When One of the Following Occurred: Sudden Cardiac Death, Sustained Ventricular Tachycardia, or…
Phase 4 N=53 Clinical and Therapeutic Implications of Fibrosis in Hypertrophic Cardiomyopathy
Myocardial Fibrosis · Hypertrophic Cardiomyopathy
Primary: Absolute Change in Serum Markers of Collagen Turnover (Micrograms/L) Over a One-year Follow-up Period in the Spironolactone Group Compared to Placebo. — 2.1; 2.1; 0.7…
Phase 2 N=6 Ranolazine Mediated PVC Reduction in Ischemic Heart Disease
Ventricular Premature Complexes · Myocardial Ischemia
Primary: The Effect of Ranolazine on the PVC Burden Over 30 Days — 5.71; 5.495 percentage of PVC burden
N/A N=145 Bipolar Ventricular Tachycardia (VT) Study
Ventricular Tachycardia
Primary: Number of Participants Achieving Freedom From Recurrent Ventricular Tachycardia (VT) — 16; 29 Participants
N/A N=23 Right Ventricular Hemodynamics Using Cardiac MRI in Patients COPD and OSA
Obstructive Sleep Apnea · Chronic Obstructive Pulmonary Disease · Overlap Syndrome
Primary: Right Ventricular Remodeling Index — 0.3747; 0.2817 ratio
Phase 4 N=1,902 Avoid DeliVering TherApies for Non-sustained Arrhythmias in ICD PatiEnts III
Heart Disease
Primary: For the Primary Endpoint the Reduction of Ventricular Therapies (ATP and Shocks) Delivered for Treating Fast Spontaneous Arrhythmia Episodes Was Measured. — 67.1; 41.9…
Phase 3 N=39 Treatment of Preclinical Hypertrophic Cardiomyopathy With Diltiazem
Hypertrophic Cardiomyopathy
Primary: Increase, Stability of, or Decrease in the Decline of Diastolic Function as Reflected by the Global Early Myocardial Relaxation (E') Velocity — -0.06; -0.21 cm/sec…